Hybio Pharmaceutical Inks Licensing Deal with Mullan Pharmaceutical for Liraglutide Biosimilar
BEIJING—Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese biopharmaceutical company, has entered into a licensing...
Deals
Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region
SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with...
Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital
BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into...
WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million
HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...
Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources
BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary,...
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co.,...
AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million
QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its...
Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases
NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE),...
Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit
LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the...
Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development
CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100...
Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech
Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347)...
Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China
Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing...
Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million
Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active...
Shanghai BDgene Partners with SPH RD to Develop Hemophilia Treatments Using BDlendi Insulator Technology
Shanghai BDgene Technology Co., Ltd, a leading gene therapy specialist based in China, has entered...
China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO
China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD...
Shenzhen Salubris Pharmaceuticals Inks Licensing Deal for YolTech Therapeutics’ YOLT-101 Gene Editing Therapy
Shenzhen Salubris Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange...
Guangzhou Boji Medical and CapitalBio Pharma Form Joint Venture to Innovate in Traditional Chinese Medicine
Guangzhou Boji Medical Biotechnological Co., Ltd, a Clinical Research Organization (CRO) based in China and...
Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...
Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round
Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for...
ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has received a USD 10 million upfront payment...